Stock Events

Stock Events

Acacia Pharma Group 

0
0
+€0.00+0% 00:00 Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Pacira BioSciences
PCRX
Mkt Cap1B
Pacira Biosciences focuses on non-opioid pain management, directly competing with Acacia's post-operative pain solutions.
Eagle Pharmaceuticals
EGRX
Mkt Cap3.29M
Eagle Pharmaceuticals specializes in hospital-based injectable products, overlapping with Acacia's focus on hospital and surgical center products.
Amphastar Pharmaceuticals
AMPH
Mkt Cap1.18B
Amphastar Pharmaceuticals manufactures injectable and inhalation products, competing in the anesthesia and critical care space with Acacia.
Heron Therapeutics
HRTX
Mkt Cap52.72M
Heron Therapeutics focuses on improving the patient experience in cancer care and acute care, which competes with Acacia's post-operative and cancer supportive care products.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap49.09B
Teva Pharmaceutical Industries offers generic and specialty medicines, including in the area of pain management, competing with Acacia's offerings.
Johnson & Johnson
JNJ
Mkt Cap657.68B
Johnson & Johnson, through its pharmaceutical division Janssen, offers a range of products that compete in the pain management and surgical care markets.
Abbvie
ABBV
Mkt Cap521.11B
AbbVie has a diverse portfolio including anesthesia and pain management products, competing with Acacia's focus areas.
Pfizer
PFE
Mkt Cap173.95B
Pfizer offers products in various therapeutic areas, including pain management, directly competing with Acacia Pharma's focus on post-operative care.

About

Acacia Pharma Group Plc, a pharmaceutical company, focuses on the development and commercialization of hospital products for surgical and cancer patients in the United States and internationally. The company's lead product includes BAREMSIS, an intravenous formulation of amisulpride that has completed Phase III clinical trials for the treatment and prophylaxis of post-operative nausea and vomiting. Its products also comprise APD403 that has completed Phase II clinical trials for the chemotherapy-induced nausea and vomiting treatment. The company was founded in 2007 and is based in Cambridge, the United Kingdom.
Show More
CEO
Employees
7
Country
United Kingdom
ISIN
GB00BYWF9Y76

Listings

STU
DE
AJ2.STU

0 Comments

Share your thoughts

FAQs

What is Acacia Pharma Group stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange Acacia Pharma Group stocks are traded under the ticker AJ2.STU.
How many employees does Acacia Pharma Group have?▼
As of November 2, 2026, the company has 7 employees.
In which sector is Acacia Pharma Group located?▼
Acacia Pharma Group operates in the Materials sector.
When did Acacia Pharma Group complete a stock split?▼
Acacia Pharma Group has not had any recent stock splits.